Literature DB >> 9731094

Appetite suppressants and valvular heart disease.

R B Devereux.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9731094     DOI： 10.1056/NEJM199809103391109

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Intelligent risk communication: can it be improved?

Authors:  Andrzej Czarnecki
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 2.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

Review 3.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

Authors:  Marcelo O Dietrich; Tamas L Horvath
Journal:  Nat Rev Drug Discov       Date:  2012-08-03       Impact factor: 84.694

Review 4.  Recent advances in clinical practice challenges and opportunities in the management of obesity.

Authors:  Andres Acosta; Barham K Abu Dayyeh; John D Port; Michael Camilleri
Journal:  Gut       Date:  2014-01-08       Impact factor: 23.059

5.  Anti-Obesity Agents and the US Food and Drug Administration.

Authors:  Martin F Casey; Jeffrey I Mechanick
Journal:  Curr Obes Rep       Date:  2014-09

Review 6.  The promises and perils of psychedelic pharmacology for psychiatry.

Authors:  Tristan D McClure-Begley; Bryan L Roth
Journal:  Nat Rev Drug Discov       Date:  2022-03-17       Impact factor: 84.694

Review 7.  Serotonergic drugs and valvular heart disease.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Expert Opin Drug Saf       Date:  2009-05       Impact factor: 4.250
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.